In a report published Thursday, Morgan Stanley analyst David Risinger downgraded the rating on Alkermes Plc ALKS from Equal-Weight to Underweight, but named a $61.00 price target.
In the report, Morgan Stanley noted, "Downgrade from E-W to UW relative to our coverage universe on expectations for weak lauroxil launch plus risk of Ampyra going generic sooner than expected.Setting a PT of $61 (12x our '16E rev), a 20% premium to the comp median of 10x."
Alkermes Plc closed on Wednesday at $67.12.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in